SEC Contract Filing

Filing Date: 2021-03-09

Document Content:
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>6
<FILENAME>cue-ex107_735.htm
<DESCRIPTION>EX-10.7
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
cue-ex107_735.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk39070372"></a><a name="_Hlk15040359"></a>Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed.&nbsp;&nbsp;Double asterisks denote omissions.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-style:normal;font-variant: normal;">EXHIBIT 10.7</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-style:normal;font-variant: normal;">FIFTH Amendment</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-style:normal;font-variant: normal;">to Collaboration, LICENSE and Option Agreement</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Fifth Amendment<font style="font-weight:bold;font-variant: small-caps;"> </font>to the Collaboration, License and Option Agreement (the <font style="font-weight:bold;">&#8220;Fifth Amendment&#8221;</font>) is entered into as of January 15, 2020 (the &#8220;<font style="font-weight:bold;">Fifth Amendment Effective Date&#8221;</font>) by and between <font style="font-weight:bold;font-variant: small-caps;">Cue Biopharma, Inc.</font><font style="font-variant: small-caps;">, </font>a Delaware corporation, having an address of 21 Erie Street, Cambridge, MA 02139 (&#8220;<font style="font-weight:bold;">Cue</font>&#8221;), and <font style="font-weight:bold;font-variant: small-caps;">LG Chem Ltd.</font>, <font style="letter-spacing:-0.15pt;">with its principal place of business at </font>LG Twin Towers, 128, Yeoui-daero, Yeongdeungpo-gu, Seoul, 07336, Republic of Korea (&#8220;<font style="font-weight:bold;">LGC</font>&#8221;). <font style="font-weight:bold;">Cue </font>and <font style="font-weight:bold;">LGC</font> may be referred to herein individually as a &#8220;<font style="font-weight:bold;">Party</font>&#8221; or collectively as the &#8220;<font style="font-weight:bold;">Parties</font>&#8221;. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-variant: small-caps;font-style:normal;text-transform:none;">Whereas,<font style="font-weight:normal;font-variant: normal;"> the Parties entered into a Collaboration, License and Option Agreement as of November 6, 2018 (the </font><font style="font-variant: normal;">&#8220;Original Agreement&#8221;</font><font style="font-weight:normal;font-variant: normal;">) that was subsequently amended on March 15, 2019 (the &#8220;</font><font style="font-variant: normal;">First Amendment</font><font style="font-weight:normal;font-variant: normal;">&#8221;), August 5, 2019 (the &#8220;</font><font style="font-variant: normal;">Second Amendment</font><font style="font-weight:normal;font-variant: normal;">&#8221;), October 29, 2019 (the &#8220;</font><font style="font-variant: normal;">Third Amendment</font><font style="font-weight:normal;font-variant: normal;">&#8221;) and December 18, 2019 (the &#8220;</font><font style="font-variant: normal;">Fourth Amendment</font><font style="font-weight:normal;font-variant: normal;">&#8221; and collectively with the Original Agreement, the First Amendment, the Second Amendment and the Third Amendment, the </font><font style="font-variant: normal;">&#8220;Agreement&#8221;</font><font style="font-weight:normal;font-variant: normal;">); </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-variant: small-caps;font-style:normal;text-transform:none;">Whereas,<font style="font-weight:normal;font-variant: normal;"> Section 4.3(c) of the Agreement establishes a term for the Parties to (i) select a Collaboration Antigen and Initial Collaboration Alleles for the CUE-103 Program, and (ii) prepare and approve a CUE-103 Initial Research Plan; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-variant: small-caps;font-style:normal;text-transform:none;">Whereas,<font style="font-weight:normal;font-variant: normal;"> the Parties desire to further extend the terms provided in Section 4.3(c); </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;">Now, Therefore, <font style="font-weight:normal;font-variant: normal;">in consideration of the foregoing premises and the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Cue and LGC hereby agree as follows:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" st